Home > Publications Database > [18F]SiTATE-PET/CT for detection of pheochromocytomas and paragangliomas: comparison of biochemical secretion, genotype and imaging metrics. > print

001     281874
005     20251127143337.0
024 7 _ |a 10.1007/s00259-025-07341-9
|2 doi
024 7 _ |a pmid:40445313
|2 pmid
024 7 _ |a pmc:PMC12589282
|2 pmc
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
037 _ _ |a DZNE-2025-01245
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Onkes, Meike
|b 0
245 _ _ |a [18F]SiTATE-PET/CT for detection of pheochromocytomas and paragangliomas: comparison of biochemical secretion, genotype and imaging metrics.
260 _ _ |a Heidelberg [u.a.]
|c 2025
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764250106_8032
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Somatostatin-receptor (SSTR)-targeting PET/CT is widely used for diagnosis and disease monitoring of pheochromocytoma / paraganglioma (PPGL). The aim of this study was to assess the potential of the novel SSTR-targeting tracer [18F]SiTATE in diagnosing PPGL by comparing imaging parameters to tumor marker levels and secretory activity in a small cohort of patients diagnosed with this rare tumor type.This retrospective study included 34 patients with histologically confirmed PPGL who underwent [18F]SiTATE-PET/CT at LMU University Hospital Munich between 10/2020 and 02/2024 as well as hormonal laboratory analysis within up to 100 days. Imaging parameters - standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion uptake (TLU) - were analyzed. Uptake was normalized to liver background (SUVmaxr, SUVmeanr). Radioligand uptake of biochemical subtypes and genotypes was compared with Mann-Whitney-U test. Correlation was tested using Spearman´s rank correlation test.The patient-based detection rate of [18F]SiTATE-PET was 96.6%. A moderate correlation was found between MTV and TLU with chromogranin A (r = 0.570-0.608, p < 0.005) and with biochemical secretion (r = 0.466-0.576, p < 0.05). Hereditary PPGL with Cluster 1 genotype showed stronger [18F]SiTATE uptake compared to sporadic PPGL (SUVmeanr: p = 0.032; SUVmaxr: p = 0.051). A subgroup comparison with [⁶⁸Ga]Ga-DOTATOC-PET/CT revealed no significant difference in uptake metrics or tumor-to-background ratios.This is the first clinical evaluation of [18F]SiTATE-PET/CT in patients with PPGL. MTV and TLU measured with [18F]SiTATE-PET/CT correlated well with the tumor marker chromogranin A in serum and with (nor)metanephrines in urine and plasma. Within the limits imposed by the small cohort, our results suggest that TLU and MTV in [18F]SiTATE-PET/CT could be used as SSTR imaging biomarker for monitoring of disease progression and secretory activity in patients with PPGL.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Catecholamines
|2 Other
650 _ 7 |a ELISA
|2 Other
650 _ 7 |a LCMS
|2 Other
650 _ 7 |a Molecular imaging
|2 Other
650 _ 7 |a PET/CT
|2 Other
650 _ 7 |a PPGL
|2 Other
650 _ 7 |a Paraganglioma
|2 Other
650 _ 7 |a Pheochromocytoma
|2 Other
650 _ 7 |a SSTR
|2 Other
650 _ 7 |a [18F]SiTATE
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Positron Emission Tomography Computed Tomography
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Pheochromocytoma: diagnostic imaging
|2 MeSH
650 _ 2 |a Pheochromocytoma: genetics
|2 MeSH
650 _ 2 |a Pheochromocytoma: metabolism
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adrenal Gland Neoplasms: diagnostic imaging
|2 MeSH
650 _ 2 |a Adrenal Gland Neoplasms: genetics
|2 MeSH
650 _ 2 |a Adrenal Gland Neoplasms: metabolism
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Paraganglioma: diagnostic imaging
|2 MeSH
650 _ 2 |a Paraganglioma: genetics
|2 MeSH
650 _ 2 |a Paraganglioma: metabolism
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
700 1 _ |a Dahlmann, Paul
|b 1
700 1 _ |a Gesenhues, Alena
|b 2
700 1 _ |a Gacula, Sean Ira G
|b 3
700 1 _ |a Mansour, Nabeel
|b 4
700 1 _ |a Schweizer, Júnia R O L
|b 5
700 1 _ |a Stüfchen, Isabel
|b 6
700 1 _ |a Lottspeich, Christian
|b 7
700 1 _ |a Wang, Katharina
|b 8
700 1 _ |a Auer, Matthias K
|b 9
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 10
|u dzne
700 1 _ |a Fischer, Alessa
|b 11
700 1 _ |a Braunschweig, Till
|b 12
700 1 _ |a Gildehaus, Franz-Josef
|b 13
700 1 _ |a Lindner, Simon
|b 14
700 1 _ |a Schmid-Tannwald, Christine
|b 15
700 1 _ |a Pfluger, Thomas
|b 16
700 1 _ |a Auernhammer, Christoph J
|b 17
700 1 _ |a Nölting, Svenja
|b 18
700 1 _ |a Werner, Rudolf A
|b 19
700 1 _ |a Reincke, Martin
|b 20
700 1 _ |a Bidlingmaier, Martin
|b 21
700 1 _ |a Kroiss, Matthias
|b 22
700 1 _ |a Völter, Friederike
|0 0000-0001-6157-0363
|b 23
773 _ _ |a 10.1007/s00259-025-07341-9
|g Vol. 52, no. 13, p. 5175 - 5188
|0 PERI:(DE-600)2098375-X
|n 13
|p 5175 - 5188
|t European journal of nuclear medicine and molecular imaging
|v 52
|y 2025
|x 1619-7070
856 4 _ |u https://pub.dzne.de/record/281874/files/DZNE-2025-01245%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281874/files/DZNE-2025-01245.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/281874/files/DZNE-2025-01245%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281874/files/DZNE-2025-01245.pdf?subformat=pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-05
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-05
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-05
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-05
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-05
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-05
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-05
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-05
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-05
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21